View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML
HHS/FDA RIN: 0910-AF79 Publication ID: Fall 2006 
Title: Financial Disclosure by Clinical Investigators(Section 610 Review) 
Abstract: FDA is undertaking a review of 21 CFR sections 54, 312.53, 312.47, 312.64, 314.50, 314.60, 314.94, 314.200, 314.300, 320.36, 330.10, 601.2, 807.31, 807.87, 807.100, 812.43, 812.110, 812.140, 814.20, 814.42, 814.112 and 860.123 under section 610 of the Regulatory Flexibility Act. The purpose of this review is to determine whether the regulations in sections 54, 312.53, 312.47, 312.64, 314.50, 314.60, 314.94, 314.200, 314.300, 320.36, 330.10, 601.2, 807.31, 807.87, 807.100, 812.43, 812.110, 812.140, 814.20, 814.42, 814.112 and 860.123 should be continued without change, or whether they should be amended or rescinded, consistent with the stated objectives of applicable statues, to minimize adverse impacts on a substantial number of small entities. FDA will consider, and is soliciting comments on, the following: (1) The continued need for the regulations in sections 54, 312.53, 312.47, 312.64, 314.50, 314.60, 314.94, 314.200, 314.300, 320.36, 330.10, 601.2, 807.31, 807.87, 807.100, 812.43, 812.110, 812.140, 814.20, 814.42, 814.112 and 860.123; (2) the nature of complaints or comments received concerning the regulations in sections 54, 312.53, 312.47, 312.64, 314.50, 314.60, 314.94, 314.200, 314.300, 320.36, 330.10, 601.2, 807.31, 807.87, 807.100, 812.43, 812.110, 812.140, 814.20, 814.42, 814.112 and 860.123; (3) the complexity of the regulations in sections 54, 312.53, 312.47, 312.64, 314.50, 314.60, 314.94, 314.200, 314.300, 320.36, 330.10, 601.2, 807.31, 807.87, 807.100, 812.43, 812.110, 812.140, 814.20, 814.42, 814.112 and 860.123; (4) the extent to which the regulations in sections 54, 312.53, 312.47, 312.64, 314.50, 314.60, 314.94, 314.200, 314.300, 320.36, 330.10, 601.2, 807.31, 807.87, 807.100, 812.43, 812.110, 812.140, 814.20, 814.42, 814.112 and 860.123 overlap, duplicate, or conflict with other regulations with other Federal, State, or governmental rules, and (5) the degree to which technology, economic conditions, or other factors have changed in the area affected by the regulations in sections 54, 312.53, 312.47, 312.64, 314.50, 314.60, 314.94, 314.200, 314.300, 320.36, 330.10, 601.2, 807.31, 807.87, 807.100, 812.43, 812.110, 812.140, 814.20, 814.42, 814.112 and 860.123. 
Agency: Department of Health and Human Services(HHS)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Prerule Stage 
Major: Undetermined  Unfunded Mandates: No 
RFA Section 610 Review: Section 610 Review 
CFR Citation: 21 CFR 54    21 CFR 312.53    21 CFR 312.57    21 CFR 312.64    21 CFR 314.50    21 CFR 314.60    21 CFR 314.94    21 CFR 314.200    21 CFR 314.300    21 CFR 320.36    21 CFR 330.10    21 CFR 601.2    21 CFR 807.31    21 CFR 807.87    21 CFR 807.100    21 CFR 812.43    21 CFR 812.110    21 CFR 812.140    21 CFR 814.20    21 CFR 814.42    21 CFR 814.112    21 CFR 860.123   
Legal Authority: 21 USC 321    21 USC 331    21 USC 351    21 USC 352    21 USC 353    21 USC 355    21 USC 356    21 USC 357    21 USC 360    21 USC 360c to 360j    21 USC 371    21 USC 372    21 USC 373    21 USC 374    21 USC 375    21 USC 376    21 USC 379    42 USC 262   
Legal Deadline:
Action Source Description Date
Other  Statutory  Planned Section 610 Review  02/02/2006 
Timetable:
Action Date FR Cite
Begin Review of Current Regulation  12/00/2006    
End Review of Current Regulation  12/00/2007    
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Federalism: No 
Included in the Regulatory Plan: No 
Agency Contact:
Howard P. Muller
Office of Regulatory Policy
Department of Health and Human Services
Food and Drug Administration
Suite 3037 (HFD-7), Center for Drug Evaluation and Research, WO 51, Room 6234, 10903 New Hampshire Avenue,
Silver Spring, MD 20993-0002
Phone:301 796-3601
Fax:301 847-8440
Email: howard.mullerjr@fda.hhs.gov

Stephen M. Ripley
Team Leader
Department of Health and Human Services
Food and Drug Administration
Suite 200N (HFM-17), Center for Biologics Evaluation and Research, 1401 Rockville Pike, Suite 200N (HFM-17),
Rockville, MD 20852-1448
Phone:301 827-6210

Elisa D. Harvey
Director, Office of Device Evaluation
Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health, Corp Room 130F (HFZ-215), 1350 Piccard Drive,
Rockville, MD 20850
Phone:301 594-1190
Fax:301 594-3076
Email: elisa.harvey@fda.hhs.gov